Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Background to Gilead's $21 Bln acquisition of Immunomedics

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 30, 2021 7:23pm

149 Views

Post# 34182797

RE:RE:Background to Gilead's $21 Bln acquisition of Immunomedics

Gilead is presenting at SABC 2021 on December 07-10, 2021 on Trodelvy in TNBC while ONCY presents on its Phase 2 IRENE study also in TNBC.

https://www.biospace.com/article/releases/gilead-s-bold-ambition-of-transforming-triple-negative-breast-cancer-treatment-to-be-highlighted-with-new-data-at-sabcs/

<< Previous

Bullboard Posts

Next >>

Top 10 pharmaceutical AI stocks